Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.41 |
| ▸ | PDE6D | O43924 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5647214 | 1.00 | KIF11 (0.48) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL5523051 | 0.95 | KIF11 (0.49) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL5517277 | 0.95 | KIF11 (0.49) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL4102093 | 0.90 | KIF11 (0.46) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL4513091 | 0.88 | KIF11 (0.48) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL5648475 | 0.88 | KIF11 (0.50) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL5649327 | 0.88 | KIF11 (0.50) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL5646819 | 0.88 | KIF11 (0.50) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL1890775 | 0.87 | KIF11 (0.46) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL5107451 | 0.86 | KIF11 (0.47) | KIF11CYP3A4KCNH2BRD4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7161002-B2 | Syntheses of quinazolinones | CYTOKINETICS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7009049-B2 | Syntheses of quinazolinones | CYTOKINETICS, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| US-20060041130-A1 | Syntheses of quinazolinones | CYTOKINETICS, INC. AND SMITHKLINE BEECHAM CORP. | 2006-02-23 | — | — | US | disclosed |
| EP-1480980-A4 | SYNTHESES OF QUINAZOLINONES | CYTOKINETICS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1480980-A2 | SYNTHESES OF QUINAZOLINONES | Cytokinetics, Inc. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040067969-A1 | Syntheses of quinazolinones | CYTOKINETICS, INCORPORATED | 2004-04-08 | — | — | US | disclosed |
| WO-2003070701-A2 | SYNTHESES OF QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067969-A1 | Syntheses of quinazolinones | NDUFS3, NDUFS2, NQO2 | KIF11 1865/4885CYP3A4 32/4885MAP1LC3B 544/4885 |
| US-20060041130-A1 | Syntheses of quinazolinones | NDUFS3, NDUFS2, NQO2 | KIF11 1865/4885CYP3A4 32/4885MAP1LC3B 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.